Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06507904 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults

StatusNot Yet Recruiting
PhasePhase 1
SponsorPfizer
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint added 5 → 6 primary endpoints
See other at-risk trials from Pfizer

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 6 more changesShow less
    • Primary completion date: Feb 12, 2027 to Feb 19, 2027
    • Study completion date: May 3, 2027 to May 10, 2027
    • Start date: Sep 15, 2026 to Sep 22, 2026
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: 12 to 13
    • Study description expanded, about 5 words
  2. Start date: Apr 17, 2026 to Sep 15, 2026
    • Primary completion date: Oct 31, 2026 to Feb 12, 2027
    • Study completion date: Oct 31, 2026 to May 3, 2027
    v4
  3. Primary and study completion dates: Oct 14, 2025 to Oct 31, 2026
    • Start date: Mar 31, 2025 to Apr 17, 2026
    v3
  4. Primary and study completion dates: Feb 26, 2025 to Oct 14, 2025
    • Start date: Aug 13, 2024 to Mar 31, 2025
    • Study title revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
436 trials monitored
See 32 trials at risk
A study to learn how different preparations of osivelotor taste and enter the blood with food or liquids, or with an antacid in healthy adults.
Trial Details
NCT Number NCT06507904
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Healthy
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov